The study's results could reshape how we evaluate cancer risk. For individuals with Barrett's esophagus, the presence of an ...

Lastly, the MANTRA-4 phase 1 study will combine milademetan with atezolizumab (PD-L1 inhibitor) in patients with CDKN2A loss and wildtype p53 advanced solid tumors (start enrollment in Q1 2023).

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer. Nature Cancer , 2025; DOI: 10.1038/s43018-024-00876-0 Cite This Page : ...

The findings could have significant implications for how we assess cancer risk. They suggest that if a person with Barrett's esophagus has an early CDKN2A mutation but no mutations in p53, it ...

The mammalian CDKN2A locus contains a gene encoding two unrelated proteins; the cyclin-dependent kinase inhibitor p16 INK4a and ARF — a regulator of p53 stability. In the Early Edition of the ...

To evaluate the yield and outcomes of 20-year perspective surveillance, researchers followed 344 subjects (median age at enrollment, 48.7 years; 41.9% men) who carried the CDKN2A gene mutation.

Background: BRAF, NRAS, CDKN2A and P53 mutations are commonly observed pathogenic mutations in cutaneous melanoma. The influence of mutations such as BRAF, NRAS, CDKN2A and P53 on treatment response ...

NGS analysis showed MDM2amplification in 1/5 HPD patient and a loss of CDKN2A/B in 4/5 patients. None of the non-HPD patients had IHC expression of MDM2 or amplification of the gene. Among the non-HPD ...

They suggest that if a person with Barrett's esophagus has an early CDKN2A mutation but no mutations in p53, it could indicate that their condition is less likely to progress to cancer.